

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) PTO Form 1449				Attorney Docket 044921-5029-01		Application No. 09/960,706			
				Applicants: William E. Munger <i>et al.</i>				Page 1 of 1	
				Filing Date: September 24, 2001		Group Art Unit: 1631			
U.S. PATENT DOCUMENTS									
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date		
<i>mm</i>	aa	2003/0134324 A1	07/17/2003	Munger <i>et al.</i>	435	7.1	06/05/2001		
FOREIGN PATENT DOCUMENTS									
		Document No.	Date	Country	Class	Sub-Class	Translation		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)									
<i>mm</i>	ab	Elsasser-Beile <i>et al.</i> , Comparison of the Activation Status of Tumor Infiltrating and Peripheral Lymphocytes of Patients with Adenocarcinomas and Benign Hyperplasia of the Prostate, (2000) The Prostate, 45:1-7							
<i>mm</i>	ac	Shidaifat <i>et al.</i> , Gossypol Arrests Human Benign Prostatic Hyperplastic Cell Growth at G0/G1 Phase of the Cell Cycle, (1997) Anticancer Res. 17:1003-1010							
Examiner <i>Ma Moran</i>				Date Considered <i>3/22/05</i>					
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/960,706
		Filing Date	9/24/2001
		First Named Inventor	William MUNGER
		Group Art Unit	1631
		Examiner Name	Moran, M.
Sheet 1	of 1	Attorney Docket Number	44921-5029-01-US

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
MAM		5,763,429		Bishop et al.	8/9/1998	
MAM		5,882,864		An et al.	3/16/1999	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		Office ³	Number ⁴	Kind Code ⁵ (if known)				


OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MAM		Bubendorf, L et al. Survey of gene amplifications during prostate cancer progression by high-throughput fluorescence in situ hybridization on tissue microarrays. (1999) Cancer Research 59:803-806.	
MAM		Bubendorf, L et al. Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. (1999) J. Nat. Cancer Inst. 91(20):1758-1764.	

Examiner Signature		Date Considered	3/22/05
-----------------------	--	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

Attorney Docket No.
44921-5029-01Application No.
09/960,706Applicants: William MUNGER *et al.*

PAGE 1 of 1

PTO Form 1449

Filing Date: September 24, 2001

Group Art Unit: ¹⁶³¹Unassigned**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Sub Class	Filing Date

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Sub Class	Translation YES NO


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Brinkman, U. <i>et al.</i> PAGE-1 AN X CHROMOSOME-LINKED GAGE-LIKE GENE THAT IS EXPRESSED IN NORMAL AND NEOPLASTIC PROSTATE, TESTIS, AND UTERUS (1998) <i>Proc. Natl. Acad. Sci. (USA)</i> 96:20767-20762
	Brinkman, U. <i>et al.</i> NOVEL GENES IN THE PAGE AND GAGE FAMILY OF TUMOR ANTIGENS FOUND BY HOMOLOGY WALKING IN THE dbEST DATABASE. (1999) <i>CANCER RES.</i> 59, 1445-148.
	Isomura, M. <i>et al.</i> ISOLATION AND MAPPING OF RAB2L, A HUMAN CDNA THAT ENCODES A PROTEIN HOMOLOGOUS TO RALGDS. (1996) <i>Cyogenet. Cell Genet.</i> 74, 263-265.
	Jacob, K. <i>et al.</i> OSTEONECTIN PROMOTES PROSTATE CANCER CELL MIGRATION AND INVASION: A POSSIBLE MECHANISM FOR METASTASIS TO BONE (1999) <i>Cancer Res.</i> 59:4453-4457
	Nollet, F. <i>et al.</i> PHYLOGENETIC ANALYSIS OF THE CADHERIN SUPERFAMILY ALLOWS IDENTIFICATION OF SIX MAJOR SUBFAMILIES BESIDES SEVERAL SOLITARY MEMBERS (2000) <i>J. Mol. Bio.</i> 299, 51-572
	Seto, M.H. <i>et al.</i> PRO FOLD ANALYSIS OF THE B30.2-LIKE DOMAIN (1999) <i>PROTEINS</i> 35:235-49
	Thomas, R. <i>et al.</i> DIFFERENTIAL EXPRESSION OF OSTEONECTIN/SPARC DURING HUMAN PROSTATE CANCER PROGRESSION (2000) <i>Clin. Cancer Res.</i> 6:1140-1149

Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0851-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete If Known

Application Number	09/960,706
Filing Date	9/24/2001
First Named Inventor	William MUNGER
Group Art Unit	1631
Examiner Name	Moran, M.
Attorney Docket Number	44921-5029-01-US

RECEIVED

AUG 23 2002

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
		5,763,429		Bishop et al.	8/9/1998	
		5,882,864		An et al.	3/16/1999	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Bubendorf, L et al. Survey of gene amplifications during prostate cancer progression by high-throughput fluorescence in situ hybridization on tissue microarrays. (1999) Cancer Research 59:803-806.	
		Bubendorf, L et al. Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. (1999) J. Nat. Cancer Inst. 91(20):1758-1764.	

Examiner
Signature

Date
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.